Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
New York, NY, based Investment company Penbrook Management LLC (Current Portfolio) buys Cohu Inc, Kulicke & Soffa Industries Inc, PubMatic Inc, Chevron Corp, Intra-Cellular Therapies Inc, sells Nuance Communications Inc, Aspen Group Inc, The One Group Hospitality Inc, Landmark Infrastructure Partners LP, Global Partners LP during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Penbrook Management LLC.
NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the completion of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share. In addition, the underwriters have exercised in full their option to purchase an additional 1,42